SCHEMBL26875162

SCHEMBL26875162

CNC(=O)C1(NC(=O)c2c3cc(OCc4cccnc4C(F)(F)F)ccc3nn2C)CCOC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.33
ADAM17 P78536 4/20 0.32
MMP3 P08254 2/20 0.32
MMP7 P09237 2/20 0.32
ADAMTS4 O75173 2/20 0.32
ADAMTS1 Q9UHI8 1/20 0.32
ADAMTS5 Q9UNA0 1/20 0.32
MMP13 P45452 3/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.31
MMP12 P39900 1/20 0.31
OPRL1 P41146 1/20 0.31
CACNA1G O43497 1/20 0.30
CACNA1H O95180 1/20 0.30
CACNA1I Q9P0X4 1/20 0.30
ALOX5 P09917 1/20 0.30
CXCR2 P25025 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
CD38 P28907 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26696044 0.93 CYP4F2 (0.34) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714569 0.93 CYP4F2 (0.34) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL26696014 0.92 ANO1 (0.33) GRM2ADAM17MMP3MMP7ADAMTS4
SCHEMBL30714574 0.92 CD38 (0.33) GRM2ADAM17MMP3MMP7ADAMTS4
SCHEMBL30714572 0.92 ANO1 (0.33) GRM2ADAM17MMP3MMP7ADAMTS4
SCHEMBL30714552 0.91 ADAM17 (0.31) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714673 0.88 CD38 (0.35) GRM2ADAM17MMP3OPRL1CACNA1G
SCHEMBL30714699 0.85 ADAM17 (0.39) ADAM17MMP3MMP7ADAMTS4ADAMTS1
SCHEMBL30714680 0.83 SCN9A (0.38) GRM2ADAM17MMP13OPRL1CACNA1G
SCHEMBL30714603 0.81 ADAM17 (0.34) GRM2ADAM17MMP13OPRL1CACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 GRM2 696/4885ADAM17 3090/4885MMP3 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.